Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma
NL-OMON56318Phase 2Recruiting
- Sponsor
- Stichting European Myeloma Network
- Start
- Dec 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (3 arms), sponsored by Stichting European Myeloma Network. Primary endpoints: Response improvement rate within 6 months and Dose reductions or discontinuation within 6 months. Started Dec 2021; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON56318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56318.